BriaCell shareholders approve quorum amendment and elect directors at annual meeting

On February13, 2023, BriaCell Therapeutics Corp. (the “Company”) amended its Articles to raise the quorum threshold for shareholder meetings to two shareholders who are, or who represent by proxy, shareholders who, in the aggregate, hold at least 33 1/3% of the outstanding shares entitled to be voted at the meeting.

Proposal 3. At the Meeting, the Company’s shareholders approved a new omnibus equity incentive plan (the “Omnibus Equity Incentive Plan”). The result of the votes to approve the Omnibus Equity Incentive Plan was as follows: For Against Abstain Broker Non-Votes 3,169,080 548,283 28,145 2,917,862

Proposal 5. At the Meeting, the Company’s shareholders authorized and approved an amendment to the Articles of the Company to raise the quorum threshold for shareholder meetings to two shareholders who are, or who represent by proxy, shareholders who, in the aggregate, hold at least 33 1/3% of the outstanding shares entitled to be voted at the meeting (the “Quorum Amendment”). The result of the votes to approve the Quorum Amendment was as follows: For Against Abstain Broker Non-Votes 3,695,624 41,488 8,396 2,917,862

Proposal 2. At the Meeting, the terms of seven (7) members of the Board expired. Each of the seven (7) nominees for director (the “Nominees”) were elected to serve until the next annual meeting of shareholders, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles of the Company or the British Columbia Corporations Act. The result of the votes to elect the Nominees was as follows: Directors For Against Withheld Broker Non-Votes Dr. Jane Gross 3,695,837 0 49,672 2,917,861 Mr. Marc Lustig 3,651,900 0 93,608 2,917,862 Mr. Jamieson Bondarenko 3,742,891 0 2,618 2,917,861 Dr. William V. Williams 3,743,095 0 2,414 2,917,861 Dr. Rebecca Taub 3,740,940 0 4,569 2,917,861 Mr. Vaughn C. Embro-Pantalony 3,733,000 0 12,508 2,917,862 Mr. Martin Schmieg 3,739,718 0 5,791 2,917,861

Proposal 1. At the Meeting, the shareholders ratified the appointment of MNP LLP as auditors for the Company and the authorization of the Board of Directors of the Company (the “Board”) to fix the auditors’ remuneration and terms of engagement. The result of the votes to ratify the appointment of MNP LLP was as follows: For Against Abstain Broker Non-Votes 6,651,809 0 11,560 1

Proposal 4. At the Meeting, upon approving the Omnibus Equity Incentive Plan, the Company’s shareholders ratified, confirmed and approved a grant of 19,200 restricted share units under the Omnibus Equity Incentive Plan to the Company’s Chief Executive Officer on August 2, 2022 (the “RSU Award”). The result of the votes to approve the RSU Award was as follows: For Against Abstain Broker Non-Votes 3,622,931 96,879 25,698 2,917,862